Repaglinide Use in Patients with Renal Impairment

Indications and Dosing in Renal Dysfunction

In adults with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) ≤ 40 mL/min/1.73 m², initiate repaglinide at 0.5 mg orally before each meal; titrate upward cautiously based on self‑monitored blood glucose. 1
For patients with severe renal impairment (eGFR 20–40 mL/min/1.73 m²), the same conservative starting dose of 0.5 mg before meals is recommended, with gradual dose escalation guided by glucose readings. [1][2]
In end‑stage renal disease (including those on hemodialysis), repaglinide may be started at 0.5 mg before meals and titrated cautiously; hemodialysis does not require additional dose adjustments. 1

Advanced CKD (stages 4–5) is associated with an increased risk of hypoglycemia when using repaglinide because of reduced drug clearance and impaired renal gluconeogenesis. [1][2]3
Clinical studies have shown that rates of minor hypoglycemia are comparable across all levels of renal function, and no major hypoglycemic episodes were reported. [1][2]3

Unlike nateglinide, repaglinide does not generate active metabolites that accumulate in renal failure, making it safer in this population. [1][2]3
First‑generation sulfonylureas should be avoided entirely in CKD; repaglinide is preferred as a safer alternative. [1][2]3
Among second‑generation sulfonylureas, glipizide is generally favored, but repaglinide provides greater dosing flexibility in patients with severe renal impairment. 1

When initiating repaglinide or adjusting its dose in patients with severe renal impairment, close blood‑glucose monitoring is essential to detect hypoglycemia early and guide dose changes. 1

All statements are based on evidence cited from peer‑reviewed studies; specific strength of evidence was not detailed in the source material.

Patients with estimated GFR ≥ 30 mL/min/1.73 m² can receive standard repaglinide dosing without adjustment. 4
In severe renal impairment (eGFR < 30 mL/min/1.73 m²), therapy should be started conservatively at 0.5 mg before each meal, with careful upward titration guided by self‑monitored blood glucose. 4

Repaglinide is primarily metabolized by the liver and does not generate active metabolites that accumulate in renal failure, making it safer than many renally‑cleared oral hypoglycemics. 4
Glyburide is contraindicated in patients with any degree of renal impairment and should be avoided. 4
Glimepiride and glipizide require conservative initiation (approximately 1 mg and 2.5 mg daily, respectively) with slow titration when eGFR < 30 mL/min/1.73 m². 4
Both meglitinides (repaglinide and nateglinide) require reduced‑dose initiation in severe renal impairment (eGFR < 30 mL/min/1.73 m²). 4

The 2022 American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not list repaglinide in their renal‑impairment dosing tables, emphasizing newer agents (SGLT2 inhibitors, GLP‑1 receptor agonists) for cardiovascular and renal protection. 5

In chronic kidney disease, clinicians should consider agents with proven cardiovascular or renal benefit—such as DPP‑4 inhibitors, GLP‑1 receptor agonists, or insulin—when selecting glucose‑lowering therapy. 5